The recognition of peptide-MHC (pMHC) complexes by T cells is the cornerstone of cellular immunity, enabling the elimination of infected or tumoral cells. pMHC can thus be leveraged as a detection tool for T cells.
Stanford scientists designed a nanobody platform to inhibit the activity of granulysin, a protein that is often found in arterial plaque and released by T cells, to prevent the development of atherosclerosis such as heart attack and strokes.
Stanford researchers have designed a nanobody platform to selectively block a key region on T cells found within arterial plaque, with the aim of preventing thrombotic complications and myocarditis.
Researchers at Stanford have developed a nanoparticle-based platform to enhance activation of self-specific CD8+ T cells in the tumor microenvironment to fight cancer while minimizing toxic side effects.
Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.
Scientists from the Davis and Mackall labs at Stanford have discovered T cell receptor molecules targeting a novel antigen upregulated in cancer. This discovery has potential value for cancer-targeting therapies, particularly CAR T therapies.
Scientists from the Davis and Mackall labs at Stanford have discovered T cell receptor molecules targeting a novel antigen upregulated in cancer. This discovery has potential value for cancer-targeting therapies, particularly CAR T therapies.
Stanford researchers have developed a molecular diagnostic for Alzheimer's disease (AD) based on their recent discovery of an immunologic signature. While innate inflammation has been implicated in AD, little is known about the role of the adaptive immune response.